These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
842 related articles for article (PubMed ID: 23737439)
1. Sclerostin regulates release of bone mineral by osteocytes by induction of carbonic anhydrase 2. Kogawa M; Wijenayaka AR; Ormsby RT; Thomas GP; Anderson PH; Bonewald LF; Findlay DM; Atkins GJ J Bone Miner Res; 2013 Dec; 28(12):2436-48. PubMed ID: 23737439 [TBL] [Abstract][Full Text] [Related]
2. Exendin-4 increases bone mineral density in type 2 diabetic OLETF rats potentially through the down-regulation of SOST/sclerostin in osteocytes. Kim JY; Lee SK; Jo KJ; Song DY; Lim DM; Park KY; Bonewald LF; Kim BJ Life Sci; 2013 Mar; 92(10):533-40. PubMed ID: 23357248 [TBL] [Abstract][Full Text] [Related]
3. Sclerostin Promotes Bone Remodeling in the Process of Tooth Movement. Shu R; Bai D; Sheu T; He Y; Yang X; Xue C; He Y; Zhao M; Han X PLoS One; 2017; 12(1):e0167312. PubMed ID: 28081119 [TBL] [Abstract][Full Text] [Related]
4. Sclerostin stimulates osteocyte support of osteoclast activity by a RANKL-dependent pathway. Wijenayaka AR; Kogawa M; Lim HP; Bonewald LF; Findlay DM; Atkins GJ PLoS One; 2011; 6(10):e25900. PubMed ID: 21991382 [TBL] [Abstract][Full Text] [Related]
5. Activation of AMP-activated protein kinase decreases receptor activator of NF-κB ligand expression and increases sclerostin expression by inhibiting the mevalonate pathway in osteocytic MLO-Y4 cells. Yokomoto-Umakoshi M; Kanazawa I; Takeno A; Tanaka K; Notsu M; Sugimoto T Biochem Biophys Res Commun; 2016 Jan; 469(4):791-6. PubMed ID: 26713363 [TBL] [Abstract][Full Text] [Related]
6. Recombinant sclerostin antagonizes effects of ex vivo mechanical loading in trabecular bone and increases osteocyte lacunar size. Kogawa M; Khalid KA; Wijenayaka AR; Ormsby RT; Evdokiou A; Anderson PH; Findlay DM; Atkins GJ Am J Physiol Cell Physiol; 2018 Jan; 314(1):C53-C61. PubMed ID: 28978523 [TBL] [Abstract][Full Text] [Related]
7. Evidence that osteocyte perilacunar remodelling contributes to polyethylene wear particle induced osteolysis. Ormsby RT; Cantley M; Kogawa M; Solomon LB; Haynes DR; Findlay DM; Atkins GJ Acta Biomater; 2016 Mar; 33():242-51. PubMed ID: 26796208 [TBL] [Abstract][Full Text] [Related]
8. Effects of high glucose and advanced glycation end products on the expressions of sclerostin and RANKL as well as apoptosis in osteocyte-like MLO-Y4-A2 cells. Tanaka K; Yamaguchi T; Kanazawa I; Sugimoto T Biochem Biophys Res Commun; 2015 May; 461(2):193-9. PubMed ID: 25721666 [TBL] [Abstract][Full Text] [Related]
9. Advanced Glycation End Product 3 (AGE3) Increases Apoptosis and the Expression of Sclerostin by Stimulating TGF-β Expression and Secretion in Osteocyte-Like MLO-Y4-A2 Cells. Notsu M; Kanazawa I; Takeno A; Yokomoto-Umakoshi M; Tanaka KI; Yamaguchi T; Sugimoto T Calcif Tissue Int; 2017 Apr; 100(4):402-411. PubMed ID: 28229177 [TBL] [Abstract][Full Text] [Related]
11. IL-6 Enhances Osteocyte-Mediated Osteoclastogenesis by Promoting JAK2 and RANKL Activity In Vitro. Wu Q; Zhou X; Huang D; Ji Y; Kang F Cell Physiol Biochem; 2017; 41(4):1360-1369. PubMed ID: 28278513 [TBL] [Abstract][Full Text] [Related]
12. Iron overload induced osteocytes apoptosis and led to bone loss in Hepcidin Ma J; Wang A; Zhang H; Liu B; Geng Y; Xu Y; Zuo G; Jia P Bone; 2022 Nov; 164():116511. PubMed ID: 35933095 [TBL] [Abstract][Full Text] [Related]
13. Pigment epithelium-derived factor (PEDF) reduced expression and synthesis of SOST/sclerostin in bone explant cultures: implication of PEDF-osteocyte gene regulation in vivo. Li F; Cain JD; Tombran-Tink J; Niyibizi C J Bone Miner Metab; 2019 Sep; 37(5):773-779. PubMed ID: 30607618 [TBL] [Abstract][Full Text] [Related]
14. Carbonic anhydrase III protects osteocytes from oxidative stress. Shi C; Uda Y; Dedic C; Azab E; Sun N; Hussein AI; Petty CA; Fulzele K; Mitterberger-Vogt MC; Zwerschke W; Pereira R; Wang K; Pajevic PD FASEB J; 2018 Jan; 32(1):440-452. PubMed ID: 28928248 [TBL] [Abstract][Full Text] [Related]
15. Osteocytes: regulating the mineral reserves? Arnett TR J Bone Miner Res; 2013 Dec; 28(12):2433-5. PubMed ID: 24166807 [No Abstract] [Full Text] [Related]
16. Osteocyte recruitment declines as the osteon fills in: interacting effects of osteocytic sclerostin and previous hip fracture on the size of cortical canals in the femoral neck. Power J; Doube M; van Bezooijen RL; Loveridge N; Reeve J Bone; 2012 May; 50(5):1107-14. PubMed ID: 22353552 [TBL] [Abstract][Full Text] [Related]
17. Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. Poole KE; van Bezooijen RL; Loveridge N; Hamersma H; Papapoulos SE; Löwik CW; Reeve J FASEB J; 2005 Nov; 19(13):1842-4. PubMed ID: 16123173 [TBL] [Abstract][Full Text] [Related]
18. Targeted disruption of BMP signaling through type IA receptor (BMPR1A) in osteocyte suppresses SOST and RANKL, leading to dramatic increase in bone mass, bone mineral density and mechanical strength. Kamiya N; Shuxian L; Yamaguchi R; Phipps M; Aruwajoye O; Adapala NS; Yuan H; Kim HK; Feng JQ Bone; 2016 Oct; 91():53-63. PubMed ID: 27402532 [TBL] [Abstract][Full Text] [Related]
19. Modulation of sclerostin expression by mechanical loading and bone morphogenetic proteins in osteogenic cells. Papanicolaou SE; Phipps RJ; Fyhrie DP; Genetos DC Biorheology; 2009; 46(5):389-99. PubMed ID: 19940355 [TBL] [Abstract][Full Text] [Related]
20. Human primary osteocyte differentiation in a 3D culture system. Boukhechba F; Balaguer T; Michiels JF; Ackermann K; Quincey D; Bouler JM; Pyerin W; Carle GF; Rochet N J Bone Miner Res; 2009 Nov; 24(11):1927-35. PubMed ID: 19419324 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]